News Focus
News Focus
icon url

KCRoyal2004

09/16/20 8:25 PM

#117244 RE: Saltz #117241

I agree with your last point, and would be surprised if there are not 1 or 2 CA lawsuits posted in the a.m., due to his claiming that he "applied for EUA about an hour ago."

Back to the DSMB, I thought that Nader said that when the FDA reviewed the safety data at 149, that they did NOT look at efficacy. I assume that interim results in a month or so WILL reveal efficacy, if present, and will be considered if substantial.
icon url

BioInvestor4

09/16/20 8:28 PM

#117245 RE: Saltz #117241

Good post.. however it’s my understanding the DSMB only looked at safety in the first look and not efficacy...
icon url

Amatuer17

09/16/20 8:35 PM

#117246 RE: Saltz #117241

It was interesting to note that NP said that - they actually did not submit EUA application but requested opinion.

This means what he said as ‘applied for EUA” was clearly misleading or plain lie.

If he had not submitted application for EUA to FDA, then I am not sure if he actually applied to MHRA and it was also consulting request.
This means he misled

Same way - he mentioned about MX trial - he was telling us that trial will finish quickly when Mx FDA even had not even received it.

This is plain lying to all of us. He needs to go
icon url

synaphai

09/16/20 9:27 PM

#117257 RE: Saltz #117241

If you are going to buy for SC I'd go with RLFTF instead as a hedge.


They should have their results sooner and their drug looks like it is as close to a slam dunk as possible for Covid.

The downside is that they have a massive number of outstanding shares and don't have real upside beyond Covid but if you are thinking about buying more CYDY just for SC then I'd go with RLFTF instead. It's what I've been doing anyway and I'm long CYDY and have been for almost 2 years.
icon url

Rockleo

09/16/20 10:34 PM

#117267 RE: Saltz #117241

Saltz..Factually there is NO need to give Leronlimab to MILD Corona patients.. In my estimation from my patient’s..About 85%. New2 above 4.. would be a STAND OUT.. These Moderate patient’s account for the ENTIRE 0.8% Mortality in the US.. Leronlimab would be IDEAL for this 15%..Stop hospital admissions..Stop intubations..ICU admissions..AND Long hauler Development..!!!

WHY have we waited 5 weeks to hear the FDA refused to entertain Leronlimab for Mild to Moderate..?? We should have started and perhaps ended that Study in 8 week for Moderate News2 ..Patients above a score of 4....!!! Long Haulers should NOT be a part of this Phase 3 MODERATE Trial..!!!

Long Haulers should be a different animal altogether..People out 6 weeks from Covid detection..WITH persistent symptoms..The fact that 30% of OUR Mild to Moderate patient’s had ZERO News2 Scores..Upsets me..AS WE UNDERMINED Leronlimab..!!!

It’s like trying a Diabetic Drug on a patient with NO diabetes..and concluding ..It’s no different than a placebo..??

Leronlimab IS the real deal ..It will save OUR NATION..

Let’s GO.. !!!
icon url

skezan

09/16/20 10:37 PM

#117271 RE: Saltz #117241

Actually, it will be us shareholders who will pay dearly tomorrow.